The GC-MS metabolomics signature in patients with fibromyalgia syndrome directs to dysbiosis as an aspect contributing factor of FMS pathophysiology.
Bontle G MalatjiCarolus J ReineckeLodewyk J MienieRon A WeversHelgard MeyerMari van ReenenCarolus J ReineckePublished in: Metabolomics : Official journal of the Metabolomic Society (2019)
Overall, urinary metabolite profiles in the FMS patients suggest: (1) energy utilization is a central aspect of this pain disorder, (2) dysbiosis seems to prevail in FMS patients, indicated by disrupted microbiota metabolites, supporting the model that microbiota may alter brain function through the gut-brain axis, with the gut being a gateway to generalized pain, and (3) screening of urine from FMS is an avenue to explore for adding non-invasive clinical information for diagnosis and treatment of FMS.
Keyphrases
- tyrosine kinase
- end stage renal disease
- ejection fraction
- chronic pain
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- resting state
- white matter
- patient reported outcomes
- neuropathic pain
- healthcare
- spinal cord injury
- functional connectivity
- spinal cord
- health information
- patient reported
- cerebral ischemia